Amini Niloufar, Khademian Majid, Momen Tooba, Saneian Hossein, Nasri Peiman, Famouri Fatemeh, Ebrahimi Giti
Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Child Growth and Development Research Center, Research Institute of Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
Int J Pediatr. 2022 Mar 7;2022:4211626. doi: 10.1155/2022/4211626. eCollection 2022.
Eosinophilic esophagitis (EoE) is an allergic inflammatory disorder of the esophagus. Today, probiotics are included as adjuvant therapy in the treatment of allergic diseases. The aim of this study was to assess the effect of synbiotic on clinical symptom improvement in EoE patients.
This study is designed by a double-blind, placebo-controlled clinical trial with two parallel groups, which was performed on 30 children with eosinophilic esophagitis. All participants were children aged 6 months to 15 years. Both groups received the same treatment (elimination diet, topical steroid, and proton pump inhibitor). A synbiotic (KidiLact) was added to the medication regimen of 15 patients (case), while the next 15 patients received a placebo (control). Severity and frequency of symptoms were assessed with a checklist derived from a validated scoring tool in both groups before and after 8 weeks of treatment.
There was a significant reduction in the severity score of chest pain and poor appetite ( value < 0.05) in the case group taking probiotics, while nausea and poor appetite were the only symptoms with a significant reduction in the frequency score after intervention in this group.
Probiotics can be used as adjuvant treatment for patients with EoE. Improvement in the severity of chest pain and poor appetite and reduction in the frequency of nausea and poor appetite in these patients can be seen.
嗜酸性粒细胞性食管炎（EoE）是一种食管的过敏性炎症性疾病。如今，益生菌被纳入过敏性疾病治疗的辅助疗法中。本研究的目的是评估合生元对EoE患者临床症状改善的效果。
本研究设计为一项双盲、安慰剂对照的平行两组临床试验，对30例嗜酸性粒细胞性食管炎患儿进行。所有参与者均为6个月至15岁的儿童。两组均接受相同的治疗（排除饮食、局部类固醇和质子泵抑制剂）。15例患者（病例组）的药物治疗方案中添加了一种合生元（KidiLact），而另外15例患者接受安慰剂（对照组）。在治疗8周前后，使用源自有效评分工具的检查表评估两组患者症状的严重程度和频率。
服用益生菌的病例组中胸痛和食欲减退的严重程度评分显著降低（P值<0.05），而恶心和食欲减退是该组干预后频率评分显著降低的仅有的症状。
益生菌可作为EoE患者的辅助治疗方法。这些患者的胸痛严重程度和食欲减退情况有所改善，恶心和食欲减退的频率降低。
